Interest based Ads

Privacy Policy Update

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy ↗. Do you want to set these advertising cookies on this browser?

For US Health Care Professionals Only
For your C3G and IgA Nephropathy patients life outside your office can be more challenging than imagined.

Your Knowledge Can Make a Difference

Complement-mediated glomerular diseases such as IgA nephropathy and C3G can cause a significant burden on patients and can potentially lead to kidney failure and transplantation.1,2

Understanding these conditions can help inform you on how to care for patients with these diseases.

Kidney icon

  • Patients with IgA nephropathy and C3G face the possibility of disease progression1,2

  • For patients who rely on supportive care and steroids to manage their disease, side effects may need to be managed3,4

  • There are no FDA-approved treatment options for IgAN or C3G that address a key pathogenic step in the progression of these diseases—activation of the complement system1,4-6

Sign up to receive complement-mediated kidney disease updates and resources

Sign Up

Learn about IgA nephropathy

Go

Learn about C3G

Go
C3G, complement 3 glomerulopathy; IgA, immunoglobulin A.
References: 1. Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129-143. 2. Lafayette RA, Kelepouris E. lmmunoglobulin A nephropathy: advances in understanding of pathogenesis and treatment. Am J Nephrol. 2018;47(suppl 1):43-52. doi:10.1159/000481636 3. Rovin BH, Adler SG, Barratt J, et al; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(suppl 4):S1-S276. 4. Feldman DL, Bomback A, Nester CN. Voice of the Patient: Report of Externally Led Patient-Focused Drug Development Meeting on Complement 3 Glomerulopathy (C3G). National Kidney Foundation; 2018. 5. Cheung CK, Rajasekaran A, Barratt J, Rizk DV. An update on the current state of management and clinical trials for IgA nephropathy. J Clin Med. 2021;10(11):2493. doi:10.3390/jcm10112493 6. Feldman DL, White EM, Julian B, et al. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy. National Kidney Foundation; 2020.